TABLE 3.

SARS‐CoV2 vaccines currently approved and/or in phase 3 clinical trials

Vaccine developer	Vaccine candidate	Vaccine platform	Phase	Route of administration	Doses	Dosing schedule
Pfizer, BioNTech	BNT162b2	RNA‐based vaccine	Phase 2/3 Approved by EMA and FDA	IM	2	Day 0 + 28
Janssen Pharmaceutical	Ad26.COV2‐S	Viral vector	Phase 3 Approved by FDA	IM	1‐2	Day 0 or Day 0 + 56
AstraZeneca, University of Oxford	AZD1222	Viral vector	Phase 3 Approved by EMA and FDA	IM	1‐2	Day 0 + 28
Moderna, NIAID	mRNA‐1273	RNA‐based vaccine	Phase 3 Approved by EMA and FDA	IM	2	Day 0 + 28
Gamaleya Research Institute	Sputnik V	Viral vector	Phase 3	IM	2	Day 0 + 21
CanSino Biological Inc	Ad5‐nCoV	Viral vector	Phase 3	IM	1	Day 0
Sinovac Biotech	Coronoa Vac	Inactivated virus	Phase 3	IM	2	Day 0 + 14
Sinopharm + Wuhan Institute of Biological Products	Vero cell	Inactivated virus	Phase 3	IM	2	Day 0 + 21
Sinopharm + Beijing Institute of Biological Products	Vero cell	Inactivated virus	Phase 3	IM	2	Day 0 + 21
Novavax	NVX‐CoV‐2373	Protein subunit	Phase 3	IM	2	Day 0 + 21
Anhui Zhifei Longcom Biopharmaceutical	CHO Cell	Protein subunit	Phase 3	IM	2‐3	Day 0 + 28 ±56
CureVac AG	CVnCoV	RNA‐based vaccine	Phase 2/3	IM	2	Day 0 + 28
Inovio Pharmaceuticals	INO‐4800 electroporation	DNA‐based vaccine	Phase 2/3	ID	2	Day 0 + 28
Bharat Biotech International Limited	BBV152	Inactivated virus	Phase 3	IM	2	Day 0 + 14